Clinical trials: High-risk Prostate Cancer
Prostate Adenocarcinoma
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy.
- Trial name
- NCT06499870
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sean Sachdev
Oligometastatic Disease, Prostate Cancer
Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma
The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to…
- Trial name
- Oli-P (NCT02264379)
- Testing
- normal fractionated irradiation, hypo fractionated irradiation
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Technische Universität Dresden
Prostate Cancer
Prostate Delineation: High Quality Volume CT
This study will look at how feasible it is to use a certain type of Computed Tomography (CT) to scan prostate cancer, called a high quality volume CT scan.
- Trial name
- NCT01878773
- Testing
- High Quality Volume CT Scan; MRI Scan
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent…
- Trial name
- NCT02692105
- Testing
- Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in patients with prostate cancer treated with radiation and hormonal therapy.
- Trial name
- NCT02588404
- Testing
- LHRH therapy
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
High Risk Prostate Cancer
Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer
Considering the promising results with hypofractionated in low and intermediate risk prostate cancer, our proposal is to translate this experience to patients with high risk prostate cancer.
- Trial name
- NCT02107287
- Testing
- IMRT Technique
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Sergio Faria
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Prostatic Neoplasms, Bone Mineral Density Quantitative Trait Locus 3
High-dose Vitamin D Supplementation for ADT-induced Side Effects
The purpose of this study is to test the efficacy of a high-dose vitamin D supplementation regimen in reducing androgen deprivation therapy (ADT)-related side effects in older prostate cancer patients on ADT.
- Trial name
- NCT02064946
- Testing
- vitamin D
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Rochester
Prostate Cancer, Localized Prostate Carcinoma
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT.
- Trial name
- NCT07455903
- Testing
- Leuprolide, Degarelix, Relugolix
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baptist Health South Florida
Prostate Cancer
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate…
- Trial name
- THUNDER (NCT06282588)
- Testing
- Darolutamide, Radiotherapy, Zoladex 3.6Mg Implant
- Where
- 9 sites in Belgium
- Volunteers
- 493 people
- Sponsor
- Cancer Research Antwerp
Metastatic Prostate Cancer
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone.
- Trial name
- VA-BAT (NCT05011383)
- Testing
- High dose testosterone
- Where
- 17 sites in United States
- Volunteers
- 51 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Detection of Minimal Residual Disease Post-prostatectomy
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to…
- Trial name
- MiRaDE (NCT07334275)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer, Stage IV Prostate Cancer
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
The goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone…
- Trial name
- NCT05189457
- Testing
- Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease.
- Trial name
- MRSI+RRP (NCT01780701)
- Testing
- Magnetic Resonance Spectroscopy Imaging with rectal probe
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Prostate Cancer
Assessment of HIFU-induced Prostate Necrosis With Shear-wave Ultrasound Elastography
Transrectal High-intensity Focused Ultrasound (HIFU) is a minimally-invasive therapy for prostate cancer that is currently assessed in two indications: as a first-line treatment (either total or focal) for patients who are not…
- Trial name
- IDITOP-1 (NCT01729442)
- Testing
- Shear-wave ultrasound elastography (SWUE)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Head and Neck Cancer, Prostate Cancer
Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers
Magnetic resonance imaging (MRI) is a diagnostic study that makes pictures of organs of the body using magnetic field and radio frequency pulses that can not be felt.
- Trial name
- NCT01535898
- Testing
- MRI scanner with sequence
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumors, Glioma
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in…
- Conditions
- Tumors, Glioma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00338026
- Testing
- ECO-4601
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Thallion Pharmaceuticals
Prostate Cancer
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma…
- Trial name
- PROSINT (NCT04147806)
- Testing
- IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine